FDA Inspection 1316850 — Novo Nordisk A/S
The FDA completed an inspection of Novo Nordisk A/S on April 17, 2026 in Malov. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- April 17, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Malov (Denmark)
Additional Details
Bioanalytical BA/BE